[BOOK][B] louis vuitton

L Vuitton, M Jacobs, K Grand - 2006 - hsleiden.nl
Op 13 november 2002 vond in de Amsterdamse PC Hooftstraat de opening plaats van de
eerste Louis Vuitton-winkel in Nederland, de 299ste ter wereld. Volgens Rudi Fuchs, de …

Echinococcosis: advances in the 21st century

H Wen, L Vuitton, T Tuxun, J Li, DA Vuitton… - Clinical microbiology …, 2019 - Am Soc Microbiol
Echinococcosis is a zoonosis caused by cestodes of the genus Echinococcus (family
Taeniidae). This serious and near-cosmopolitan disease continues to be a significant public …

[HTML][HTML] Clinical epidemiology of human AE in Europe

…, C Richou, F Grenouillet, A Chauchet, L Vuitton… - Veterinary …, 2015 - Elsevier
This review gives a critical update of the situation regarding alveolar echinococcosis (AE) in
Europe in humans, based on existing publications and on findings of national and European …

Outcomes of endoscopic ultrasound-guided biliary drainage: A systematic review and meta-analysis

…, S Grabar, A Zhang, S Koch, L Vuitton… - United European …, 2019 - journals.sagepub.com
Background Success and event rates of endoscopic ultrasound (EUS)-guided biliary
drainage vary with techniques, and results from different studies remain inconsistent …

[PDF][PDF] MOËT HENNESSY♦ LOUIS VUITTON

LMHL Vuitton - 2012 - r.lvmh-static.com
This second supplement (the “Second Supplement”) is supplemental to, and should be read
in conjunction with, the Base Prospectus dated 2 July 2014 prepared in relation to the€ …

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease

…, B Pereira, L Peyrin‐Biroulet, L Vuitton… - UEG …, 2021 - Wiley Online Library
Background Preventing postoperative recurrence (POR) is a major concern in Crohn's
disease (CD). While azathioprine is an option, no data is available on ustekinumab efficacy …

Biologic agents for IBD: practical insights

S Danese, L Vuitton, L Peyrin-Biroulet - … reviews Gastroenterology & …, 2015 - nature.com
Six biologic agents are currently approved for the treatment of IBD: four anti-TNF agents
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus

L Vuitton, L Peyrin‐Biroulet… - Alimentary …, 2017 - Wiley Online Library
Background Recently, endpoints for clinical trials have been changing from measuring
clinical response to mucosal healing in ulcerative colitis. Endoscopic evaluation is the …

Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease

…, G Savoye, J Moreau, C Gagniere, L Vuitton… - Clinical …, 2016 - Elsevier
Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We …

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

L Vuitton, P Marteau, WJ Sandborn, BG Levesque… - Gut, 2016 - gut.bmj.com
Background Crohn's disease (CD) is a chronic disabling and progressive IBD. Only
strategies looking beyond symptoms and based on tight monitoring of objective signs of …